Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KB2 | Q9UBS0 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.38 |
| ▸ | WNT3A | P56704 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.37 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 2/20 | 0.36 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | GALR1 | P47211 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27238090 | 0.94 | RPS6KB2 (0.41) | RPS6KB2HPGDMAPTMEN1KMT2A | |
| SCHEMBL15873586 | 0.71 | RPS6KB2 (0.50) | RPS6KB2HPGDMAPTMEN1KMT2A | |
| SCHEMBL9784218 | 0.71 | CTNNB1 (0.50) | RPS6KB2HPGDMAPTCTNNB1WNT3A | |
| Fluoride SCHEMBL491501 | 0.71 | L3MBTL1 (0.55) | RPS6KB2HPGDMAPTMEN1KMT2A | |
| SCHEMBL5746764 | 0.71 | NPC1 (0.39) | RPS6KB2HPGDMAPTMEN1KMT2A | |
| SCHEMBL25204309 | 0.69 | NISCH (0.46) | RPS6KB2HPGDMAPTMEN1KMT2A | |
| SCHEMBL7135870 | 0.69 | MAPT (0.52) | RPS6KB2HPGDMAPTMEN1KMT2A | |
| SCHEMBL498605 | 0.69 | LTA4H (0.43) | RPS6KB2HPGDMAPTMEN1KMT2A | |
| SCHEMBL667254 | 0.69 | KDM4E (0.43) | RPS6KB2HPGDMAPTMEN1KMT2A | |
| SCHEMBL6910633 | 0.68 | NISCH (0.44) | RPS6KB2HPGDMAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6787570-B2 | ADMINISTERING AN AROMATIC OR HETEROAROMATIC SUBSTITUTED TERTIARYAMINE COMPOUND TO TREAT ATHEROSCLEROSIS, DYSLIPIDEMIA, AND OTHER CORONARY ARTERY DISEASES | PFIZER, INC. | 2004-09-07 | — | — | US | claimed |
| US-8518975-B2 | Gamma secretase modulators | Merck Sharp + Dohme Corp. (US) | 2013-08-27 | — | — | US | disclosed |
| US-20110082153-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION | 2011-04-07 | — | — | US | disclosed |
| EP-2200990-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION (US) | 2010-06-30 | — | — | EP | disclosed |
| WO-2009032277-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION (US) | 2009-03-12 | — | — | WO | disclosed |
| US-7081533-B2 | Phosphorus compounds used as catalysts for asymmetric hydrogenation, hydroformylation, rearrangement, alkylation, cyclization, hydrosilation, hydrocyanation or aldol condensation | DEGUSSA AG (DE) | 2006-07-25 | — | — | US | disclosed |
| EP-1311517-B1 | CYCLOALIPHATIC/AROMATIC DIPHOSPHINES AND USE THEREOF IN CATALYSIS | DEGUSSA (DE) | 2004-07-14 | — | — | EP | disclosed |
| US-20040019205-A1 | Phosphorus compounds used as catalysts for asymmetric hydrogenation, hydroformylation, rearrangement, alkylation, cyclization, hydrosilation, hydrocyanation or aldol condensation | DEGUSSA AG (DE) | 2004-01-29 | — | — | US | disclosed |
| EP-1311517-A1 | CYCLOALIPHATIC/AROMATIC DIPHOSPHINES AND USE THEREOF IN CATALYSIS | Degussa AG (DE) | 2003-05-21 | — | — | EP | disclosed |
| WO-2002014330-A1 | CYCLOALIPHATIC/AROMATIC DIPHOSPHINES AND USE THEREOF IN CATALYSIS | DEGUSSA AG (DE) | 2002-02-21 | — | — | WO | disclosed |
| US-5352687-A | Hypotensive agents | BAYER AKTIENGESELLSCHAFT (DE) | 1994-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082153-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | RPS6KB2 503/4885HPGD 1744/4885MAPT 325/4885 |
| US-20040019205-A1 | Phosphorus compounds used as catalysts for asymmetric hydrogenation, hydroformylation, rearrangement, alkylation, cyclization, hydrosilation, hydrocyanation or aldol condensation | GNPAT, PNKP, PHOSPHO1 | RPS6KB2 4242/4885HPGD 2221/4885MAPT 2757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.